| Resum: |
There is a need to evaluate the professionals' perception about the consequences of the lack of therapeutic adherence in the evolution of patients with co-occurring disorders. An online survey, released on the Socidrogalcohol [Spanish Scientific Society for Research on Alcohol, Alcoholism and other Drug Addictions] and Sociedad Española de Patología Dual [the Spanish Society of Dual Pathology] web pages, was answered by 250 professionals who work in different types of Spanish health centers where dual diagnosis patients are assisted. Most professionals perceived the existence of noncompliance among dual diagnosis patients. Almost all of these professionals (99%) perceived that noncompliance leads to a worsening of the progression of the patient's disorder, in both the exacerbation of mental disorders and the consumption of addictive substances. Most of the professionals (69. 2%) considered therapeutic alliance as the main aspect to take into account to improve the prognosis in this population. The primary purpose of treatment must be the improvement of psychotic-phase positive symptoms, followed by the control of behavior disorders, reduction of craving, improvement of social and personal performances, and reduction of psychotic-phase negative symptoms. Most professionals perceived low adherence among dual diagnosis patients. This lack of adherence is associated with a worsening of their disease evolution, which is reflected in exacerbations of the psychopathology and relapse in substance use. Therefore, we propose to identify strategies to improve adherence. |
| Nota: |
Altres ajuts: The editorial support of this article, as well as the survey on which it was based, were financed by Janssen. Carlos Roncero has received fees to give talks for Janssen-Cilag S.A., Bristol-Myers Squibb, Ferrer-Brainpharma, Pfizer, Reckitt Benckiser/Indivior, Lundbeck, Otsuka, Servier, Lilly, Shire, GlaxoSmithKline, and AstraZeneca. He has received financial compensation for his participation as a member of the Janssen-Cilag S.A., Lilly, and Shire boards. He has carried out the PROTEUS project, which was funded by a grant from Reckitt Benckiser. Néstor Szerman has received speaker fees from Janssen-Cilag S.A., Lundbeck, Servier, and Lilly. He has received financial compensation for his participation as a member of the Janssen-Cilag S.A. and Lundbeck boards. Antonio Terán has received fees to give talks for Lilly, Janssen, Pfizer, Shire, Lundbeck, GlaxoSmithKline, and Servier. He has received financial compensation for his participation as a member of the Janssen-Cilag S.A., Lilly, Reckitt Benckiser, and Lundbeck boards. Carlos Pino has received financial compensation from the following laboratories: Janssen-Cilag S.A., Lilly, Servier, Ferrer, Lundbeck, Almirall, Reckitt Benckiser, Wyeth, and Esteve. He has received financial compensation for his participation as a member of the Janssen-Cilag board. José María Vázquez has received financial compensation from the following laboratories: Janssen-Cilag S.A., Lilly, Lundbeck, Bristol Myers Squibb, Reckitt Benckiser, and Juste. He has received financial compensation for his participation as a member of the Janssen board. Elena Velasco and Marta García-Dorado work in the Medical Affairs Department of Janssen-Cilag S.A. Miguel Casas has received fees to give talks for JanssenCilag S.A., Bristol-Myers Squibb, Ferrer-Brainpharma, Pfizer, Reckitt-Benckiser, Lundbeck, Otsuka, Servier, Lilly, Shire, GlaxoSmithKline, Rovi, and Adamed. He has received financial compensation for his participation as a member of the Janssen-Cilag S.A., Lilly, and Shire boards. |
visitant ::
identificació
(Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
